LDS/Medical Tests/Chlamydia trachomatis NAAT, Urine

Chlamydia trachomatis NAAT, Urine

Chlamydia trachomatis is the most commonly acquired notifiable sexually transmitted disease (STD) in the US. Chlamydia trachomatis, also known as chlamydia, is responsible for close to 1 million new infections each year. This is almost three times the number of reported gonorrhea infections. One reason that chlamydia is more prevalent than gonorrhea is that women often have symptoms that are too mild or nonspecific for them to seek medical treatment. This results in chlamydia being 3 times more prevalent in women than men.

Transmission of chlamydia is typically by direct contact with infected secretions, usually from sexual contact; however, transmission from mother to child may occur through vaginal delivery, or to other family members through poor hygiene. Commonly infected sites are genitalia, the eyes, throat, and rectum. Chlamydia can cause disease with symptoms that range from none to moderate. Once infected, approximately 70 - 90% of individuals experience no or relatively mild symptoms. If left untreated, permanent damage to the reproductive organs can result leading to infertility in both males and females. Untreated disease can lead to serious complications including pelvic inflammatory disease and infertility in women. Infection during pregnancy can lead to premature births, ectopic pregnancies, infant conjunctivitis, and pneumonia, as well as maternal postpartum endometritis. Among men, urethritis, prostatitis, epididymitis, and infertility are the most common illnesses. Chlamydia directly damages infected host cells, and damage also occurs as a result of inflammation, a response of the host-immune system. Chlamydia infections do not have a strong or long-lasting immune response, therefore, infection does not protect against re-infection.

There are at least 15 serovars of C. trachomatis that are recognized as causing infections in humans: the trachoma serovars, A-C; the occulogenital serovars D-K; and the lymphogranuloma venereum serovars, L1 – L3. Diagnostic methods for the identification of C. trachomatis infection include culture and immunological assays; however, nucleic acid testing has been shown to be more sensitive and specific and is the method of choice. Specimen types include vaginal, endocervical, and urethral swabs, urine and cytology media.

  • Screening for Chlamydia trachomatis infection
  • Evaluation of pelvic inflammatory disease
  • As an aid in evaluation of cervicitis
  • As an aid in evaluation of urethritis and epididymitis in men
  • As an aid in diagnosis of trachoma, conjunctivitis, pneumonia
  • Useful in confirmation for diagnosis of Chlamydia trachomatis

Positive (Detected) in:

  • Chlamydia trachomatis infection
  • Pelvic inflammatory disease
  • Cervicitis in women, and urethritis, epididymitis in men
  • Trachomatis and conjunctivitis
  • Pneumonia
  • Infertility

Negative (Not Detected)

 

Transcription Mediated Amplification (TMA) technology, Polymerase Chain Reaction (PCR), Strand Displacement Amplification

Urine collected in a sterile container. 

Stability

    • Ambient: 3-5 days
    • Refrigerated: 5-7 days
    • Frozen: 30 days
C. trachomatis and N. gonorrhoeae culture if indicated, Pap smear, Human Papillomavirus (HPV) by molecular method, Herpes simplex virus by PCR or culture, Ureaplasma urealiticum, Mycoplasma homini, Trichomonas vaginali, Yeast culture, Genital culture for other vaginosis and vaginitits.

1-3 days.

Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login